Ioannis Mantzaris, MD
Hematology-Oncology · Bronx, NYNPI 1871865519
Payments from drug & device makers
Across 246 payments — averaging $8534.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi US Services Inc.$1.1M
- Janssen Research & Development, LLC$289K
- Jazz Pharmaceuticals Inc.$285K
- Trillium Therapeutics USA, LLC$254K
- E.r. Squibb & Sons, L.L.C.$96K
- Bayer$24K
- plus $75K from 19 others
Across 3 payments — averaging $962.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$2K
- Bristol Myers Squibb$591
- AbbVie$20
What the payments were for
- Consulting fees$2,50073%
- Food & beverage$86425%
- Education$431%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi US Services Inc. | 45 | $1,076,341 |
| Janssen Research & Development, LLC | 71 | $288,730 |
| Jazz Pharmaceuticals Inc. | 15 | $284,614 |
| Trillium Therapeutics USA, LLC | 30 | $253,947 |
| E.r. Squibb & Sons, L.L.C. | 5 | $96,349 |
| Bayer | 11 | $24,267 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $22,687 |
| AbbVie | 11 | $19,861 |
| Syndax Pharmaceuticals, Inc. | 2 | $13,295 |
| Seagen Inc. | 6 | $6,755 |
| Eli Lilly | 1 | $4,458 |
| Bristol Myers Squibb | 1 | $4,050 |
| Gilead | 17 | $2,947 |
| Stemline Therapeutics Inc. | 1 | $845 |
| Johnson & Johnson | 4 | $75 |
| Pfizer | 3 | $57 |
| Sanofi-aventis U.S. LLC | 2 | $49 |
| AstraZeneca | 1 | $43 |
| Acrotech Biopharma Inc. | 1 | $37 |
| Merck | 1 | $24 |
| Astellas Pharma US Inc | 1 | $20 |
| Genentech USA, Inc. | 1 | $16 |
| Spectrum Pharmaceuticals Inc. | 1 | $16 |
| Sanofi | 1 | $11 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecartus$2,500
How this compares
$2,099,507 in reported general payments places this provider in the 95th percentile of 38 hematology-oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 20 | $325,740 |
| ValacyclovirValacyclovir Hcl | 48 | $2,835 |
| Atorvastatin Calcium | 17 | $64 |
| Metoprolol Succinate | 11 | $63 |
Paid to pharmacies, not to this prescriber.
Other hematology-oncology in Bronx
- Amy SharmaBronx$11K
- Xuan GeBronx$4K
- Joachim FuksBronx$204
- Robert LopezBronx$0
- Jacob GlassNew York$42K
- Anna UrazovBrooklyn$5K
- Sherry HsuNew York$4K
- Nirmala ShevdeNew Hyde Park$3K
- Rana DouliRego Park$2K
- Neha MaithelBrooklyn$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.